Author(s):
Pinki Verma, Kuruva Akhilesh Reddy, Atif Khan, Syed Masih Ulla, Mir Razi Abbas, Md. Azeemuddin
Email(s):
vermapinki05@gmail.com
DOI:
10.52711/2231-5713.2026.00036 
Address:
Pinki Verma1*, Kuruva Akhilesh Reddy2, Atif Khan3, Syed Masih Ulla4, Mir Razi Abbas5, Md. Azeemuddin6
1Associate Professor, Department of Pharmacology, Aditya Bangalore Institute of Pharmacy Education and Research, Rajiv Gandhi University of Health Sciences, Yelahanka, Bengaluru, 560064 Karnataka, India.
2Research Scholar, Department of Pharmacology, Aditya Bangalore Institute of Pharmacy Education and Research, Rajiv Gandhi University of Health Sciences, Yelahanka, Bengaluru, 560064 Karnataka, India.
3Research Scholar, Department of Pharmacology, Aditya Bangalore Institute of Pharmacy Education and Research, Rajiv Gandhi University of Health Sciences, Yelahanka, Bengaluru, 560064 Karnataka, India.
4Research Scholar, Department of Pharmacology, Aditya Bangalore Institute of Pharmacy Education and Research, Rajiv Gandhi University of Health Sciences, Yelahanka, Bengaluru, 560064 Karnataka, India.
5Research Scholar, Department of Pharmacology, Aditya Bangalore Institute of Phar
Published In:
Volume - 16,
Issue - 3,
Year - 2026
ABSTRACT:
Background: The convergence of traditional herbal medicine with cutting-edge scientific advancements has given rise to Tridox C. This next-generation phototherapeutic agent harmonizes ethnomedicine, pharmacogenomics, and nanotechnology to address the limitations of conventional herbal treatments. Despite the widespread use of plant-based remedies, challenges such as poor bioavailability, inconsistent efficacy, and interindividual variability have hindered their integration into evidence-based medicine. Main Body: Tridox C overcomes these barriers through a multi-disciplinary approach. Ethnomedicine forms its foundation, incorporating botanicals with well-documented historical use (e.g., curcumin, withanolides, bacosides) that are selected based on traditional knowledge and validated through modern studies. To mitigate issues like low solubility and rapid metabolism, Tridox C employs nanotechnology-driven delivery systems, including liposomal encapsulation, polymeric nanoparticles, and nanoemulsions. These enhance solubility, prolong circulation time, and enable targeted tissue delivery. A groundbreaking aspect is its integration with pharmacogenomics, allowing for personalized therapy. By analyzing genetic polymorphisms, Tridox C can be tailored to an individual’s genetic makeup, maximizing efficacy and minimizing adverse effects. This precision medicine approach is further refined using AI-driven predictive modelling. Preliminary studies suggest Tridox C’s potential in managing chronic inflammatory diseases, neurodegenerative disorders, and metabolic syndromes. However, challenges remain, including regulatory hurdles for nano-herbal formulations, the scalability of personalized medicine, and ethical considerations regarding ethnomedical knowledge appropriation. Conclusion: This review synthesizes current research on Tridox C, highlighting its innovative framework, mechanisms of action, and therapeutic potential. By bridging traditional wisdom with 21st-century biotechnology, Tridox C exemplifies the future of precision herbal medicine, offering a blueprint for safer, more effective, and individualized phototherapeutics. Further clinical validation and interdisciplinary collaboration will be crucial in translating this promising paradigm from bench to bedside.
Cite this article:
Pinki Verma, Kuruva Akhilesh Reddy, Atif Khan, Syed Masih Ulla, Mir Razi Abbas, Md. Azeemuddin. Unveiling Tridox C: Integrating Ethnomedicine, Pharmacogenomics and Nanotechnology for Next-Generation Herbal Therapeutics. Asian Journal of Pharmacy and Technology. 2026; 16(3):249-8. doi: 10.52711/2231-5713.2026.00036
Cite(Electronic):
Pinki Verma, Kuruva Akhilesh Reddy, Atif Khan, Syed Masih Ulla, Mir Razi Abbas, Md. Azeemuddin. Unveiling Tridox C: Integrating Ethnomedicine, Pharmacogenomics and Nanotechnology for Next-Generation Herbal Therapeutics. Asian Journal of Pharmacy and Technology. 2026; 16(3):249-8. doi: 10.52711/2231-5713.2026.00036 Available on: https://ajptonline.com/AbstractView.aspx?PID=2026-16-3-6
11. REFERENCES:
1. World Health Organization. WHO Traditional Medicine Strategy: 2014–2023. Geneva: WHO; 2013.
2. Yuan H, Ma Q, Ye L, Piao G. The traditional medicine and modern medicine from natural products. Molecules. 2016; 21(5): 559.
3. Heinrich M, Appendino G, Efferth T. Best research practice—Overcoming common challenges in phytopharmacological research. J Ethnopharmacol. 2020; 246: 112230.
4. Patra JK, Das G, Fraceto LF. Nano-based drug delivery systems: Recent developments and prospects. J Nanobiotechnology. 2018; 16(1): 71.
5. Gonzalez-Sarrias A, Garcia-Villalba R, Nunez-Sanchez MA, et al. Identifying the limits for ellagic acid bioavailability: A crossover pharmacokinetic study in healthy volunteers after consumption of pomegranate extracts. J Funct Foods. 2015; 19: 225-235.
6. Prasad S, Aggarwal BB. Turmeric, the golden spice: from traditional medicine to modern medicine. In: Benzie IFF, Wachtel-Galor S, editors. Herbal Medicine: Biomolecular and Clinical Aspects. 2nd edition. Boca Raton (FL): CRC Press; 2011. Chapter 13.
7. Dutta R, Khalil R, Green R, Mohapatra SS, Mohapatra S. Withania somnifera (Ashwagandha) and Withaferin A: Potential in Integrative Oncology. Int J Mol Sci. 2019; 20(22): 5310.
8. Mukherjee PK, Banerjee S, Biswas S, Das B, Kar A, Katiyar CK. Withania somnifera (L.) Dunal - Modern perspectives of an ancient Rasayana from Ayurveda. J Ethnopharmacol. 2021; 264: 113157.
9. Singh HK, Dhawan BN. Neuropsychopharmacological effects of the Ayurvedic nootropic Bacopa monniera Linn. (Brahmi). Indian J Pharmacol. 1997;29: S359-65.
10. Kulkarni R, Girish KJ, Kumar A. Nootropic herbs (Medhya Rasayana) in Ayurveda: An update. Pharmacognosy Rev. 2012; 6(11): 55-62.
11. Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev. 2009;14(2): 141-53.
12. Rastogi S, Pandey MM, Rawat AKS. Traditional herbs: a remedy for cardiovascular disorders. Phytomedicine. 2016; 23(2):1082-9.
13. Williamson EM. The evolution of pharmacopoeias: a global perspective. J Ethnopharmacol. 2021; 267:113500.
14. Patwardhan B, Warude D, Pushpangadan P, Bhatt N. Ayurveda and traditional Chinese medicine: a comparative overview. Evid Based Complement Alternat Med. 2005; 2(4): 465-73.
15. Gohil KJ, Patel JA. A review on Bacopa monniera: Current research and future prospects. Int J Green Pharm. 2010; 4(1): 1-9.
16. Heinrich M, Jäger AK, editors. Ethnopharmacology. Chichester: Wiley-Blackwell; 2015.
17. Fabricant DS, Farnsworth NR. The value of plants used in traditional medicine for drug discovery. Environ Health Perspect. 2001; 109 Suppl 1(Suppl 1): 69-75.
18. Gurib-Fakim A. Medicinal plants: traditions of yesterday and drugs of tomorrow. Mol Aspects Med. 2006; 27(1): 1-93.
19. Anyinam C. Ecology and ethnomedicine: exploring links between current environmental crisis and indigenous medical practices. Soc Sci Med. 1995; 40(3): 321-9.
20. Yuan H, Ma Q, Ye L, Piao G. The traditional medicine and modern medicine from natural products. Molecules. 2016; 21(5): 559.
21. Atanasov AG, Waltenberger B, Pferschy-Wenzig EM. Discovery and resupply of pharmacologically active plant-derived natural products: a review. Biotechnology Adv. 2015; 33(8): 1582-614.
22. Gertsch J. Botanical drugs, synergy, and network pharmacology: forth and back to intelligent mixtures. Planta Med. 2011; 77(11): 1086-98.
23. Patwardhan B, Vaidya ADB, Chorghade M. Ayurveda and natural products drug discovery. Curr Sci. 2004; 86(6): 789-99.
24. World Health Organization. WHO traditional medicine strategy: 2014-2023. Geneva: WHO; 2013.
25. Patwardhan B, Warude D, Pushpangadan P, Bhatt N. Ayurveda and traditional Chinese medicine: a comparative overview. Evid Based Complement Alternat Med. 2005; 2(4):465-73.
26. Pushpangadan P, George V. Ethnopharmacology and IPR. J Ethnopharmacol. 2010; 132(1): 1-3.
27. Tilburt JC, Kaptchuk TJ. Herbal medicine research and global health: an ethical analysis. Bull World Health Organ. 2008; 86(8): 594-9.
28. Heinrich M, Lardos A, Leonti M, et al. Best research practice: Consensus Statement on Ethnopharmacological Field Studies. J Ethnopharmacol. 2018; 211: 329-39.
29. Kunle OF, Egharevba HO, Ahmadu PO. Standardization of herbal medicines – A review. Int J Biodivers Conserv. 2012;4(3):101–12.
30. Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol. 2014; 4: 177.
31. World Health Organization. WHO guidelines for assessing quality of herbal medicines regarding contaminants and residues. Geneva: WHO Press; 2007.
32. Mukherjee PK, Harwansh RK, Bahadur S, Banerjee S, Kar A, Chanda J, et al. Development of Ayurveda – tradition to trend. J Ethnopharmacol. 2017; 197: 10–24.
33. Zhou SF, Xue CC, Yu XQ, et al. Pharmacogenomics of traditional herbal medicine: a new path for personalized medicine. Curr Pharmacogenomics Person Med. 2010; 8(4): 255-63.
34. Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev. 2006; 58(3): 521-90.
35. Chen XW, Serag ES, Sneed KB. Clinical herbal interactions with conventional drugs: from molecules to maladies. Curr Med Chem. 2011; 18(31): 4836-50.
36. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med. 2011; 364(12): 1144-53.
37. Kennedy DO. Phytochemicals for improving aspects of cognitive function and psychological state potentially relevant to sports performance. Sports Med. 2019; 49(Suppl 1): 39-58.
38. Giacomini KM, Huang SM, Tweedie DJ. Membrane transporters in drug development. Nat Rev Drug Discov. 2010; 9(3): 215-36.
39. Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry. 2010; 15(5): 473-500.
40. Wu AH. Use of genetic and nongenetic factors in warfarin dosing algorithms. Pharmacogenomics. 2007; 8(7): 851-61.
41. Cho WC, Chung WS, Lee S. Ginsenoside Re of Panax ginseng possesses significant antioxidant and antihyperlipidemic efficacies in streptozotocin-induced diabetic rats. Eur J Pharmacol. 2006; 550(1-3): 173-9.
42. Yang L, Price ET, Chang CW, et al. Gene expression variability in human hepatic drug metabolizing enzymes and transporters. PLoS One. 2013; 8(4): e60368.
43. Mrazek DA. Psychiatric pharmacogenomic testing in clinical practice. Dialogues Clin Neurosci. 2010; 12(1): 69-76.
44. Haga SB, Burke W, Ginsburg GS, et al. Primary care physicians' knowledge of and experience with pharmacogenetic testing. Clin Genet. 2012; 82(4): 388-94.
45. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44-56.
46. Jiang F, Jiang Y, Zhi H, et al. Artificial intelligence in healthcare: past, present and future. Stroke Vasc Neurol. 2017;2(4):230-43.
47. Rajkomar A, Dean J, Kohane I. Machine learning in medicine. N Engl J Med. 2019; 380(14):1347-58.
48. Bate A, Hobbiger SF. Artificial intelligence, real-world automation and the safety of medicines. Drug Saf. 2021; 44(2): 125-32.
49. Kshetri N. Blockchain and sustainable manufacturing. IT Prof. 2021;23(3):35-39.
50. Patra JK, Das G, Fraceto LF. Nano-based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018; 16(1): 71.
51. Sur S, Rathore A, Dave V. Recent developments in functionalized polymer nanoparticles for efficient drug delivery systems. Nano-Struct Nano-Objects. 2019; 20: 100397.
52. Date T, Nimbalkar V, Kamat J, et al. Lipid nanocarriers for enhancement of oral bioavailability and therapeutic efficacy of herbal medicines. In: Grumezescu AM, editor. Nanoarchitectonics in Biomedicine. William Andrew; 2019. p. 579-609.
53. Dhas NL, Ige PP, Kudarha RR. Design, optimization and in vivo performance of solid lipid nanoparticles fabricated using ligand exchange mechanism. Int J Pharm. 2020; 588:119772.
54. Pandey P, Dahiya M. A brief review on inorganic nanoparticles. J Crit Rev. 2016; 3(3): 18-26.
55. Patra JK, Das G, Fraceto LF, et al. Nano-based drug delivery systems: recent developments and prospects. J Nanobiotechnology. 2018; 16(1): 71.
56. Sur S, Rathore A, Dave V, et al. Recent developments in functionalized polymer nanoparticles for an efficient drug delivery system. Nano-Struct Nano-Objects. 2019; 20: 100397.
57. Date T, Nimbalkar V, Kamat J, et al. Lipid nanocarriers for enhancement of oral bioavailability and therapeutic efficacy of herbal medicines. In: Grumezescu AM, editor. Nanoarchitectonics in Biomedicine. William Andrew; 2019. p. 579-609.
58. Dhas NL, Ige PP, Kudarha RR. Design, optimization and in-vivo performance of solid lipid nanoparticles fabricated using ligand exchange mechanism. Int J Pharm. 2020; 588: 119772.
59. Pandey P, Dahiya M. A brief review on inorganic nanoparticles. J Crit Rev. 2016; 3(3): 18-26.
60. Hossen S, Khalid MI, Sukreet S. Pharmacokinetics and biodistribution of engineered nanoparticles in herbal medicine delivery. Drug Metab Rev. 2022; 54(1): 1-18.
61. European Medicines Agency. Guideline on the quality requirements of nanomedicines. EMA/CHMP/13099/2013. 2018.
62. Jeevanandam J, Barhoum A, Chan YS. Toxicity of inorganic nanoparticles in biomedical applications. Nanomaterials. 2022; 12(5): 786.
63. Sahoo SK, Parveen S, Panda JJ. The present and future of nanotechnology in herbal medicine. J Herb Med. 2021; 28:100450.
64. World Health Organization. WHO guidelines on safety monitoring of herbal medicines in pharmacovigilance systems. Geneva: WHO Press; 2021.
65. Heinrich M, Appendino G, Efferth T. Best research practice - Overcoming common challenges in phytopharmacological research. J Ethnopharmacol. 2020; 246: 112230.
66. Wagner H, Ulrich-Merzenich G. Synergy research: Approaching a new generation of phytopharmaceuticals. Phytomedicine. 2009; 16(2-3): 97-110.
67. Date T, Nimbalkar V, Kamat J. Lipid nanocarriers for enhancement of oral bioavailability and therapeutic efficacy of herbal medicines. In: Grumezescu AM, editor. Nanoarchitectonics in Biomedicine. William Andrew; 2019. p. 579-609.
68. Yuan H, Ma Q, Ye L. The traditional medicine and modern medicine from natural products. Molecules. 2016;21(5):559.
69. Efferth T, Koch E. Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy. Curr Drug Targets. 2011; 12(1): 122-32.
70. Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clinical Pharmacology and Therapeutics. 2020 Apr; 107(4): 804-812. doi:10.1002/cpt.1768. Epub 2019 Dec 17.
71. Date T, Nimbalkar V, Kamat J, Mittal K, Mahato RI, Chitkara D. Lipid nanocarriers for enhancement of oral bioavailability and therapeutic efficacy of herbal medicines. In: Grumezescu AM, editor. Nanoarchitectonics in Biomedicine. Norwich, NY: William Andrew Publishing; 2019. p. 579-609. doi:10.1016/B978-0-12-816200-2.00018-2.
72. Yuan H, Ma Q, Ye L, Piao G. The traditional medicine and modern medicine from natural products. Molecules. 2016 May; 21(5): 559. doi:10.3390/molecules21050559. PMID: 27136524.
73. Patel R, Singh SK, Singh S, Sheth NR, Gendle R. Development and characterization of curcumin-loaded transfersomes for transdermal delivery. Journal of Pharmaceutical Sciences. 2009 Dec;98(12):4894-913. doi:10.1002/jps.21762.
74. Muthu MS, Feng SS. Pharmaceutical stability aspects of nanomedicines. Nanomedicine. 2009 Dec; 4(8): 857-60. doi:10.2217/nnm.09.81.
75. World Health Organization. WHO guidelines on good herbal processing practices for herbal medicines. WHO Technical Report Series, No. 1010. Geneva: WHO Press; 2018.
76. Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clinical Pharmacology and Therapeutics. 2020 Apr; 107(4): 804-12. doi:10.1002/cpt 1768.
77. Tandon N, Yadav SS. Contributions of the Indian Council of Medical Research (ICMR) in the area of medicinal plants/traditional medicine. Indian Journal of Medical Research. 2018 Nov;148(5):568-78. doi: 10.4103/ijmr.IJMR_534_18.
78. McDougall JJ. Arthritis and pain. Neurogenic origin of joint pain. Arthritis Research and Therapy. 2006; 8(6): 220. doi:10.1186/ar2069.
79. Saraiva C, Praça C, Ferreira R, Santos T, Ferreira L, Bernardino L. Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases. Journal of Controlled Release. 2016 Oct 28; 235: 34-47. doi: 10.1016/j.jconrel.2016.05.044.
80. Mandel S, Amit T, Reznichenko L, Weinreb O, Youdim MB. Green tea catechins as brain-permeable, natural iron chelators-antioxidants for the treatment of neurodegenerative disorders. Molecular Nutrition and Food Research. 2006 Feb; 50(2): 229-34. doi:10.1002/mnfr.. 200500156.
81. Tabassum N, Ahmad F. Role of natural herbs in the treatment of hypertension. Pharmacognosy Reviews. 2011 Jan; 5(9): 30-40. doi:10.4103/0973-7847.79097.
82. Gullett NP, Ruhul Amin AR, Bayraktar S, Pezzuto JM, Shin DM, Khuri FR, et al. Cancer prevention with natural compounds. Seminars in Oncology. 2010 Jun; 37(3): 58-81. doi: 10.1053/j.seminoncol.2010.06.014.
83. Zhang L, Wang Y, Yang D. Pluronic-based nano vehicles: Current advances in improved botanical drug delivery. Expert Opinion on Drug Delivery. 2020; 17(7): 949-964. doi:10.1080/17425247.2020.1767583.
84. ClinicalTrials.gov. Phase II study of nano-curcumin in rheumatoid arthritis (NCT04372056). 2021. Available from: https://clinicaltrials.gov/ct2/show/NCT04372056
85. World Health Organization. WHO technical report series no. 1010: Guidelines on quality control of herbal medicines with novel dosage forms. Geneva: WHO Press; 2021.
86. European Medicines Agency. Reflection paper on the data requirements for intravenous liposomal products developed regarding an innovator liposomal product. EMA/CHMP/806058/2009/Rev. 02. 2018.
87. Gupta R, Srivastava D, Sahu M, et al. Artificial intelligence to deep learning: Machine intelligence approach for drug discovery. Molecular Diversity. 2021; 25(3): 1315-1360. doi:10.1007/s11030-021-10217-3.